Endotoxin, sepsis, and the primrose path.
O'Reilly
M
M
Department of Anesthesiology, University of Michigan, Ann Arbor 48109-0602, USA.
Newcomb
D E
DE
Remick
D
D
D000818:Animals; D002986:Clinical Trials as Topic; D003422:Critical Care; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000502:physiology*; D004195:Disease Models, Animal; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004731:Endotoxins / Q000009:adverse effects* / Q000633:toxicity; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D051379:Mice; D008809:Mice, Inbred C3H; D009102:Multiple Organ Failure / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D011323:Primates; D011817:Rabbits; D051381:Rats; D018805:Sepsis / Q000150:complications* / Q000401:mortality; D012772:Shock, Septic / Q000150:complications / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D012795:Sialoglycoproteins / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D016207:Cytokines; D004731:Endotoxins; C507763:IL1RN protein, human; C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha